Botha FJ - Search Results

1

Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.

Botha FJ, Sirgel FA, Parkin DP, van de Wal BW, Donald PR, Mitchison DA. Botha FJ, et al. S Afr Med J. 1996 Feb;86(2):155-8. S Afr Med J. 1996. PMID: 8619142

2

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.

Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt BJ, Donald PR, van Jaarsveld PP. Parkin DP, et al. Among authors: botha fj. Am J Respir Crit Care Med. 1997 May;155(5):1717-22. doi: 10.1164/ajrccm.155.5.9154882. Am J Respir Crit Care Med. 1997. PMID: 9154882 Clinical Trial.

3

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.

Donald PR, Sirgel FA, Botha FJ, Seifart HI, Parkin DP, Vandenplas ML, Van de Wal BW, Maritz JS, Mitchison DA. Donald PR, et al. Among authors: botha fj. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):895-900. doi: 10.1164/ajrccm.156.3.9609132. Am J Respir Crit Care Med. 1997. PMID: 9310010 Clinical Trial.

4

The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis.

Sirgel FA, Botha FJ, Parkin DP, Van de Wal BW, Schall R, Donald PR, Mitchison DA. Sirgel FA, et al. Among authors: botha fj. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):901-5. doi: 10.1164/ajrccm.156.3.9611066. Am J Respir Crit Care Med. 1997. PMID: 9310011 Clinical Trial.

5

Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis.

Donald PR, Sirgel FA, Kanyok TP, Danziger LH, Venter A, Botha FJ, Parkin DP, Seifart HI, Van De Wal BW, Maritz JS, Mitchison DA. Donald PR, et al. Among authors: botha fj. Antimicrob Agents Chemother. 2000 Dec;44(12):3285-7. doi: 10.1128/AAC.44.12.3285-3287.2000. Antimicrob Agents Chemother. 2000. PMID: 11083628 Free PMC article.

6

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment.

Sirgel FA, Botha FJ, Parkin DP, Van De Wal BW, Donald PR, Clark PK, Mitchison DA. Sirgel FA, et al. Among authors: botha fj. J Antimicrob Chemother. 1993 Dec;32(6):867-75. doi: 10.1093/jac/32.6.867. J Antimicrob Chemother. 1993. PMID: 8144427 Clinical Trial.

7

Population screening for isoniazid acetylator phenotype.

Seifart HI, Parkin DP, Botha FJ, Donald PR, Van Der Walt BJ. Seifart HI, et al. Among authors: botha fj. Pharmacoepidemiol Drug Saf. 2001 Mar-Apr;10(2):127-34. doi: 10.1002/pds.570. Pharmacoepidemiol Drug Saf. 2001. PMID: 11499851

8

Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient.

Botha FJ, van der Bijl P, Seifart HI, Parkin DP. Botha FJ, et al. Intensive Care Med. 1996 May;22(5):443-6. doi: 10.1007/BF01712162. Intensive Care Med. 1996. PMID: 8796397

9

Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury.

Poeppl W, Zeitlinger M, Donath O, Wurm G, Müller M, Botha F, Illievich UM, Burgmann H. Poeppl W, et al. Int J Antimicrob Agents. 2012 Apr;39(4):343-5. doi: 10.1016/j.ijantimicag.2011.11.019. Epub 2012 Feb 9. Int J Antimicrob Agents. 2012. PMID: 22325119

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters